1-4 of 4
Ping Min
Close
Sort by
Journal Articles

Olverembatinib (HQP1351) Enhances Antitumor Effects of Chemotherapy in Philadelphia Chromosome-Positive (Ph⁺) Acute Lymphoblastic Leukemia (ALL)

Eric Liang, Ping Min, Yan Xiong, Bingxing Wu, Huidan Yu, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 5882.
https://doi.org/10.1182/blood-2023-189315
Published: 2023
Journal Articles

Embryonic Ectoderm Development (EED) Inhibitor APG5918 Improves Chronic Kidney Disease- (CKD)-Induced Hemoglobin Insufficiency in Preclinical Models of Anemia

Yifan Zhai, Yan Yin, Eric Liang, Hengbang Wang, Ping Min, Dajun Yang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5268.
https://doi.org/10.1182/blood-2023-185127
Published: 2023
Journal Articles

MDM2-p53 Inhibitor Alrizomadlin (APG-115) Enhances Antitumor Activity of Pomalidomide in Multiple Myeloma (MM)

Guangfeng Wang, Eric Liang, Ping Min, Yangfeng Ge, Bingxing Wu, Huidan Yu, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2022) 140 (Supplement 1): 9953–9954.
https://doi.org/10.1182/blood-2022-162666
Published: 2022
Journal Articles

A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation

Xiufen Zheng, Costin Vladau, Xusheng Zhang, Motohiko Suzuki, Thomas E. Ichim, Zhu-Xu Zhang, Mu Li, Ewa Carrier, Bertha Garcia, Anthony M. Jevnikar, Wei-Ping Min
Journal: Blood
Blood (2009) 113 (12): 2646–2654.
https://doi.org/10.1182/blood-2008-04-151191
Published: 2009
Includes: Supplemental data